These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 12765938

  • 1. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
    Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI.
    Diabetes; 2003 Jun; 52(6):1311-8. PubMed ID: 12765938
    [Abstract] [Full Text] [Related]

  • 2. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM.
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [Abstract] [Full Text] [Related]

  • 3. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
    Oakes ND, Thalén PG, Jacinto SM, Ljung B.
    Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
    Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ.
    Metabolism; 2003 Aug; 52(8):1078-83. PubMed ID: 12898477
    [Abstract] [Full Text] [Related]

  • 5. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
    Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF.
    Diabetes; 2002 Mar; 51(3):797-802. PubMed ID: 11872682
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
    Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW.
    Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
    Li J, Xue YM, Zhu B, Pan YH, Zhang Y, Wang C, Li Y.
    J Diabetes Res; 2018 Oct; 2018():4627842. PubMed ID: 30225267
    [Abstract] [Full Text] [Related]

  • 9. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV.
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.
    Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK.
    Diabetes; 2004 Apr; 53(4):1060-7. PubMed ID: 15047622
    [Abstract] [Full Text] [Related]

  • 11. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
    Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K, Fleckner J.
    Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
    [Abstract] [Full Text] [Related]

  • 14. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF, Purushotham A, Wendel AA, Belury MA.
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [Abstract] [Full Text] [Related]

  • 15. Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.
    Kanoh Y, Bandyopadhyay G, Sajan MP, Standaert ML, Farese RV.
    Endocrinology; 2001 Apr; 142(4):1595-605. PubMed ID: 11250941
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
    Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY, Xia ZY.
    Br J Pharmacol; 2005 Sep; 146(2):234-43. PubMed ID: 15997237
    [Abstract] [Full Text] [Related]

  • 17. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB, Hawley JA.
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart.
    Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ, Cline G, Li H, Prentki M, Shulman GI, Mitchell GA, Kim JK.
    Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E30-9. PubMed ID: 15701680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.